Aptus Pharma files FY26 Annual Report; revenue up 89.65%

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹290.60

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+1.7% vs market

Pharmaceuticals peers, median of 176sector-0.2%+2.2% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 2.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0+0.3+1.7-0.2+2.2

Next day

+4.0-0.2+4.2-0.5+4.5

+6.1+0.4+5.7-0.1+6.1

+8.2+0.2+8.0-0.0+8.2

+10.4+0.5+9.9+0.5+9.9

+8.4+0.8+7.6+0.5+7.9

+6.0-0.8+6.8+0.7+5.3

15d

+19.3-2.1+21.4+0.2+19.0

+19.8+0.2+19.5+2.0+17.7

+65.8-9.2+74.9-6.7+72.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 176Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aptus Pharma submitted its FY26 Annual Report and 16th AGM notice (September 14, 2026). Revenue rose to 4,657.46 lakh rupees from 2,455.77 lakh (up 89.65%); PAT grew to 461.99 lakh from 309.96 lakh (up 49.05%); EBITDA reached 750.32 lakh vs 475.70 lakh. First annual report post September 2025 BSE SME listing.

Likely market impact

Strong growth in first listed year; bonus issue already done, preferential share issue of about 44.88 crore rupees pending member approval.